Q&A: Anita Nelson, MD, on etonogestrel implant's 5-year approval and REMS certification

In January 2026, Contemporary OB/GYN previously reported that the FDA approved a supplemental New Drug Application extending the duration of use for the etonogestrel implant (Nexplanon) from 3 years to up to 5 years, based on data from a multicenter, single-arm, open-label study (NCT04626596) conducted in the United States.¹